Patients with acromegaly need the constant and effective medical examination due to with more frequent development of the respiratory, cardiovascular, metabolic abnormalities and neoplasia processes, causing early morbidity and premature mortality, exceeding the one in population in 2 or 4 fold. Nowadays in Russia the work is being actively done to create the Database of patients with acromegaly. It will permit to evaluate the real prevalence of acromegaly in Russia, to analyze the sufficiency of the kinds of treatment being applied before, to evaluate the efficiency of new methods of surgical and medical treatment. By the present time in the database there are included 123 patients with active and non-active phases of acromegaly, at the age from 17 to 84 years old. (Men –48, women –75). During the patients' examination the following complications were revealed: microadenoma pituitary in 65%, macroadenoma – in 35%. The arterial hypertension, cardiomegaly, hypertrophy of the left ventricle were found in 93% of patients, atherosclerosal cardiosclerosis with dilatation of heart's caverns and the development the relative valve insufficiency in 60%, diffusive and/or nodal goiter – in 69%. In 12% of cases there were revealed the polyps of the large intestine, 20% of patients had the impaired glucose tolerance or demonstrative diabetes mellitus type 2. In case of women the frequency of myoma of the uterus, fibrose-adenomatous mastopathy, the cancer of the mamma made up accordingly 17, 15 and 3%. The patients were undertaken by the following kinds of treatment: transcranial or transnasal adenomectomy –55 of them, external pituitary radiotherapy (Gamma radiotherapy, proton irradiation) –33, using the dopamine agonists (Bromocriptine, Cabergoline) –26, somatostatin analogs (Sandostatin LAR) –21 of the patients. As a result of the examination done the complete remission of the disease (circulating insulin-like growth factor-I (IGF-I) is reduces to an-adjusted normal range and nadir growth hormone (GH) after an oral glucose load is <1 ng/ml, the absence of the tumor's growth and clinical signs of the disease) was revealed: after neurosurgical treatment -15 patients (27%), after the radiation treatment –7 patients (21%), after using of the dopamine agonists –3 patients (11%), after using of Sandostatin LAR- 19 patients (90%). According to our data, the neurosurgical selective adenomectomy and therapy with the long-acting somatostatin analogs induced a fast and effective clinical and biochemical response in the majority of acromegalic patients. While using the dopamine agonists the positive effect was exposed only with patients with mixed tumors (somatoprolactinomas). Remission after radiotherapy was revealed within 5–10 years after irradiation. The applying of sandostatin LAR (20–30mg) both as a pre-operational medicine and as primary treatment made it possible with most patients to reach the stable clinical and biochemical remission, to increase the quality of life and prevent the complications' development. Though the big cost of the medicine limits its wide application. In conclusion, our results showed that the timely diagnosis of the disease, introduction of contemporary and unificated methods of diagnosis and treatment of patients in clinical practice would significantly permit to increase the length of life of acromegaly patients.